Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is -97.70% lower on its value in year-to-date trading and has touched a low of $0.22 and a high of $11.26 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MRNS stock was last observed hovering at around $0.24 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $0.26, the stock is -7.66% and -49.49% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.58 million and changing 8.07% at the moment leaves the stock -87.38% off its SMA200. MRNS registered -97.60% loss for a year compared to 6-month loss of -80.15%. The firm has a 50-day simple moving average (SMA 50) of $0.54026 and a 200-day simple moving average (SMA200) of $2.079215.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -23.05% gain in the last 1 month and extending the period to 3 months gives it a -85.63%, and is 1.26% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.17% over the week and 7.76% over the month.
Marinus Pharmaceuticals Inc (MRNS) has around 165 employees, a market worth around $15.33M and $31.47M in sales. Profit margin for the company is -446.49%. Distance from 52-week low is 16.80% and -97.72% from its 52-week high. The company has generated returns on investments over the last 12 months (-1275.80%).
with sales reaching $10.33M over the same period.The EPS is expected to grow by 22.86% this year, but quarterly earnings will post 12.20% year-over-year. Quarterly sales are estimated to grow 43.74% in year-over-year returns.
108.0 institutions hold shares in Marinus Pharmaceuticals Inc (MRNS), with institutional investors hold 93.24% of the company’s shares. The shares outstanding are 55.19M, and float is at 41.87M with Short Float at 10.30%. Institutions hold 83.04% of the Float.
The top institutional shareholder in the company is TANG CAPITAL MANAGEMENT LLC with over 4.8 million shares valued at $5.62 million. The investor’s holdings represent 8.443 of the MRNS Shares outstanding. As of 2024-06-30, the second largest holder is SOFINNOVA INVESTMENTS, INC. with 4.15 million shares valued at $4.86 million to account for 7.3025 of the shares outstanding. The other top investors are WOODLINE PARTNERS LP which holds 3.98 million shares representing 7 and valued at over $4.66 million, while SUVRETTA CAPITAL MANAGEMENT, LLC holds 6.7192 of the shares totaling 3.82 million with a market value of $4.47 million.
Marinus Pharmaceuticals Inc (MRNS) Insider Activity
Marinus Pharmaceuticals Inc disclosed in a document filed with the SEC on Aug 05 ’24 that Pfanstiel Steven (CFO AND COO) sold a total of 4,657 shares of the company’s common stock. The trade occurred on Aug 05 ’24 and was made at $1.13 per share for $5262.0. Following the transaction, the insider now directly holds 79773.0 shares of the MRNS stock.
Still, SEC filings show that on Aug 05 ’24, Shafer Christina (CHIEF COMMERCIAL OFFICER) disposed off 3,820 shares at an average price of $1.14 for $4355.0. The insider now directly holds 67,406 shares of Marinus Pharmaceuticals Inc (MRNS).
